Aspen Pharmacare Holdings Limited proposed to acquire Sigma Pharmaceuticals (Australia) Pty Ltd and two other entities from Sigma Company Limited. Sigma Pharmaceuticals (Australia) includes Sigma's pharmaceutical products manufacturing, marketing and supply business including in respect of all prescription, generic and private label products.
The ACCC will not oppose the proposed acquisition of Sigma Pharmaceuticals Limited's Pharmaceutic...
Issued: 16th December 2010 Release # NR 276/10
Review timeline
Date
Event
6th September 2010
ACCC commenced review under the Merger Review Process Guidelines.
27th September 2010
Closing date for submissions from interested parties.
8th October 2010
ACCC requested further information from the merger parties. ACCC timeline suspended.
20th October 2010
ACCC received further information from the merger parties. ACCC timeline recommenced.
27th October 2010
ACCC published a Statement of Issues outlining preliminary competition concerns.
11th November 2010
Closing date for submissions relating to Statement of Issues.
12th November 2010
ACCC received further information from the merger parties. Former proposed date for announcement of ACCC's findings of 25 November 2010 amended to allow for consideration of the information provided.
30th November 2010
Draft 87B undertaking proffered by Aspen. ACCC commenced market inquiries on the draft undertaking.
7th December 2010
Closing date for submissions relating to draft 87B undertaking.
16th December 2010
ACCC announced it would not oppose the proposed acquisition, subject to court enforceable undertaking offered by Aspen Pharmacare Holdings Limited and Aspen Asia Pacific Pty Ltd, and in light of Aspen deciding to excise Sigma's iron polymaltose product, Ferrosig, from the acquisition.
16th December 2010
87B undertaking accepted by ACCC.
* Total Review days = Total business days less public holidays and time during which the review was suspended.
